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Temozolomide is an oral alkylating agent that readily crosses the blood–brain barrier and has activity in patients with advanced
melanoma. Carboplatin is a convenient outpatient treatment that also has activity in patients with melanoma. The purpose of this
study was to assess the safety of a combination of temozolomide and carboplatin, and provide preliminary evidence of efficacy. In all,
30 patients were treated in two stages. In stage 1, patients received temozolomide 750mgm
 2, with escalating doses of carboplatin
AUC 3–6. In stage 2, patients received temozolomide 1000mgm
 2, with increasing doses of carboplatin until dose-limiting toxicity
(DLT) was experienced. In stage 1, 12 patients received 33 cycles of treatment. No grade 3/4 haematological toxicity was
experienced up to carboplatin AUC 6. In stage 2, 18 patients received 55 cycles of treatment. The DLT was haematological with
grade 4 myelosuppression seen with carboplatin AUC 5. In all, 11 patients were treated with carboplatin AUC 4 to gain further
information on toxicity. Myelosuppression remained significant and common with grade 4 thrombocytopenia experienced in 50% of
cycles. Two of 28 patients (7%) assessable for efficacy achieved a partial response. None of the 11 patients with brain metastases
responded to treatment. The addition of carboplatin to temozolomide 1000mgm
 2 significantly adds to toxicity with frequent grade
3/4 myelosuppression. Preliminary information on efficacy demonstrates that it is unlikely that the combination can be given in doses
sufficient to improve on the efficacy of temozolomide alone.
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Patients with advanced melanoma have a poor prognosis, despite
the use of chemotherapeutic and biological agents. Response rates
to cytotoxic agents are generally poor, although a number of
agents have activity. The most active agent is thought to be
dacarbazine (DTIC) with a response rate of 11–25%; however,
responses are not durable, and the median survival for this group
of patients is 4.5–6 months (Lee et al, 1995). Combination
chemotherapy has not added significantly to outcome. The
Dartmouth regimen, comprising DTIC, cisplatin, carmustine and
tamoxifen initially demonstrated a response rate of 55% in 20
patients treated (Del Prete et al, 1984). Subsequent single-centre
phase II trials confirmed response rates of 40–50% (McClay et al,
1992; Richards et al, 1992), but this was not substantiated in phase
III randomised trials. A randomised trial examining the contribu-
tion of tamoxifen to the regimen showed response rates of 20–
30%, but no benefit from its addition (Rusthoven et al, 1996).
Recently, single-agent DTIC has been compared to the Dartmouth
regimen in a randomised-controlled trial, with no difference in
survival between the two treatment arms being seen. There was a
nonsignificant increase in the response rate with the combination
arm. Toxicity, particularly relating to myelosuppression, was
significantly increased with the Dartmouth regimen (Chapman
et al, 1999). As chemotherapy for this group of patients is
palliative, improvements in tolerability and ease of administration
are worth investigating.
Temozolomide is an oral alkylating agent of the imidazotetra-
zine group, with a broad spectrum of antitumour activity. Its
active metabolite (MTIC) is the same as that of dacarbazine (Tsang
et al, 1991). It was developed as a potential alternative to DTIC
and was found to have 490% oral bioavailability, and extensive
tissue distribution, including penetration of the blood–brain
barrier and the cerebrospinal fluid (CSF) (Stevens et al, 1987).
This is particularly advantageous in patients with metastatic
melanoma, as up to 75% of patients develop brain metastases
(Dreiling et al, 1996). The initial phase I study demonstrated
that temozolomide is well tolerated with a maximum tolerated
dose (MTD) of 1000mgm
 2 (given as 200mgm
 2 once a day
over 5 consecutive days). The dose-limiting toxicity (DLT) is
myelosuppression with a nadir at 21 days and recovery usually
by 28 days. Mild to moderate emesis occurs in approximately
a third of patients, but is easily controlled with standard
antiemetics. Prolonged or severe emesis is unusual (Newlands
et al, 1992). A phase II trial of temozolomide conducted in
patients with metastatic melanoma demonstrated an objective
response rate of 21%, with three complete responses and
nine partial responses in 56 evaluable patients (Bleehen et al,
1995). In a randomised phase III trial of 305 patients, temozolo-
mide was compared to DTIC and demonstrated equal efficacy
with improved health-related quality of life (Middleton et al,
2000).
Platinum compounds have been evaluated in the treatment of
metastatic melanoma, both alone and in combination. Single-agent
cisplatin yields responses of over 10% (Al-Sarraf et al, 1982) and
has also been used in combination with DTIC in phase II trials,
showing responses of over 30% (Murren et al, 1991). The Received 12 May 2003; revised 18 July 2003; accepted 15 August 2003
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lcombination is better tolerated than other combinations including
the Dartmouth regimen, and avoids the delayed myelosuppressive
problems associated with carmustine. These results, however, have
not been evaluated in any phase III trials. Carboplatin has similar
single-agent activity to cisplatin, with a dose of 400mgm
 2
demonstrating a response rate of 16% in a phase II trial of 23
patients (Evans et al, 1987). Carboplatin is an attractive alternative
to cisplatin because of the ease of administration and favourable
side effect profile.
Temozolomide and carboplatin have not previously been used
in combination, but is a potentially attractive regimen as
carboplatin is administered as a short intravenous infusion, which
can be given in an outpatient setting unlike cisplatin-containing
therapies, and temozolomide is given orally. There is the potential
for overlapping toxicities especially relating to myelosuppression,
but the median time to nadir leucocyte and platelet count is
different for the two drugs. Other toxicities are expected to be
uncommon. The combination of temozolomide and carboplatin
potentially offers patients with advanced melanoma an improve-
ment in efficacy with a convenient regimen.
The primary aim of the trial was to treat cohorts of patients
with advanced melanoma with escalating doses of carboplatin
and temozolomide to establish the MTD and DLT of this
combination. The trial was conducted in two stages, the first with
temozolomide at a dose of 750mgm
 2, and the second at a dose of
1000mgm
 2. We report on the principal toxicities of the
combination of carboplatin and temozolomide and provide
preliminary data of efficacy, in patients with bidimensionally
measurable disease.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed, unresectable or metastatic,
malignant melanoma, with measurable or assessable lesions, were
eligible for the study. Patients were required to be over 18 years,
have a life expectancy of at least 3 months and have an Eastern
Cooperative Oncology Group (ECOG) performance status of o2.
No prior chemotherapy was allowed, but radiotherapy was
permissible to nonindicator lesions completed at least 3 weeks
prior to entry. Eligibility criteria included Hb 410gdl
 1, WBC
43 10
9l
 1, platelets 4100 10
9l
 1, serum creatinine of
o120mmoll
 1 or creatinine clearance of 450mlmin
 1, bilirubin
o30mmoll
 1, AST o3 upper limit of normal (ULN) and
alkaline phosphatase o3 ULN. Written informed consent was
obtained from all patients prior to entry. The study had local
ethical and scientific committee approval.
Pretreatment investigations
Blood investigations including full blood count, renal function and
liver function were measured. Renal function was measured using
51Cr-EDTA clearance technique, and urinalysis was also per-
formed. Radiological assessment of site/s of disease was carried out
with computer tomography (CT), magnetic resonance imaging
(MRI) or clinical photographic measurement, as appropriate.
Chest radiograph and ECG were performed.
Treatment schedule
In the first stage, patients in cohort 1 were given carboplatin AUC
3 intravenously on day 1, and temozolomide 150mgm
 2
administered orally for 5 days. Treatment was given at 28-day
intervals for up to six cycles. In successive cohorts, doses of
carboplatin were increased by AUC 1 until AUC 6 was reached. In
stage 2, patients in the first cohort were given temozolomide
200mgm
 2 orally for 5 days and carboplatin AUC 3 intravenously
on day 1, at 28-day intervals, up to six cycles. Carboplatin dose was
escalated by AUC 1 in further cohorts until DLT was experienced.
Patients who responded to treatment, or had stable disease on
completion of six cycles of the combination were eligible for
continuation of temozolomide alone for six further cycles of
treatment in accordance with the regimen used in the phase III
trial comparing temozolomide with DTIC, where up to 12 cycles of
treatment were permitted (Middleton et al, 2000).
Study design
Cohorts of three patients were treated at escalating doses of the
study drugs. Patients were assessed for CALGB expanded Common
Toxicity Criteria prior to each treatment cycle. At each dose level,
the first patient was observed for 3 weeks or until recovery from
acute toxicity (4 weeks for grade 4 toxicity) before further patients
were entered at the same dose level. The DLT was defined as grade
3 or 4 haematological toxicity, grade 4 nonhaematological toxicity
or grade 2 cardiac or pulmonary toxicity. Dose escalation was
considered when at least three patients had been entered at a given
dose, and two patients followed for 3 weeks or until all acute
toxicities had resolved. If no patients in a cohort had unacceptable
toxicity, dose escalation was undertaken. If one of three patients
had unacceptable toxicity, then three further patients were treated
at the same dose. The DLT level was reached when two of three
patients experienced DLT. A minimum of 10 patients were to be
treated at the dose level immediately below which DLT was
experienced in an attempt to establish the MTD.
Toxicity evaluation and dose modification for toxicity
Patients were evaluated for toxicity prior to each treatment cycle,
and full blood count and renal and liver function tests were
performed. Nadir full blood counts were measured on days 15 and
22 of each cycle. The ANC was required to be 41.5 10
9l
 1 and
the platelet count 4100 10
9l
 1 on day 28 for further treatment.
The use of growth factors to maintain dose was not permitted.
Dose modification was specified according to toxicity. Chemother-
apy was delayed for up to 1 week without modification if ANC
count on day 28 was 1–1.5 10
9l
 1 or platelet count 450–
o100 10
9l
 1. If ANC was o1 10
9l
 1 or platelet count
o50 10
9l
 1 on day 28, treatment was delayed until recovery
and carboplatin dose reduced by AUC¼1. Dose delays of 42
weeks constituted unacceptable toxicity and chemotherapy was
withdrawn.
All nonhaematological toxicity 4grade 1 was required to have
resolved to grade 1 or baseline prior to repeat dosing. No
dose adjustments were made for resolved grade 2 toxicity. In
patients with grade 3 nonhaematological toxicity, the dose
of carboplatin was reduced by AUC 1 for further cycles of
treatment. Patients experiencing grade 4 nonhaematological
toxicity, unless considered unrelated to study drugs, were
withdrawn from the study.
Response assessment
Prior to treatment, patients underwent clinical and radiological
assessment of site/s of disease with radiographs, CT or MRI where
appropriate. Patients could be assessed for response or progressive
disease if they received one or more cycles of treatment, although
radiological response was assessed after every two cycles of
treatment. Patients could be assessed for progressive disease after
one cycle of treatment if symptoms dictated. Tumour response was
defined according to EORTC response criteria (Therasse et al,
2000). Further investigations were undertaken according to clinical
evaluation.
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lRESULTS
Patient characteristics
In all, 30 patients with a median age of 54 years were treated
between December 1998 and January 2001. Of these, 22 patients
had multiple sites of metastases and 11 had brain metastases.
Patient characteristics are listed in Table 1.
Treatment
In total, 30 patients received 89 cycles of treatment (Table 2). In
stage 1, at temozolomide 750mgm
 2, 12 patients received 33
cycles of treatment. The median number of courses per patient was
two (range 1–6). One patient completed six cycles of treatment. No
patients experienced DLT. In stage 2 (temozolomide 1000mgm
 2),
18 patients received 56 cycles of treatment. The median number of
courses was two (range 1–6). Five patients completed six courses
of treatment, of whom two continued on temozolomide alone (at
1000mgm
 2) for a further six cycles.
Haematological toxicity
Stage 1 Mild myelosuppression was the most common toxicity
observed, but no patients experienced grade 3/4 toxicity. There
was one delay for neutropenia. There were no dose reductions
(Table 3).
Stage 2 In stage 2, in all cohorts, 53 cycles of treatment were
evaluable for toxicity. No patients experienced significant haema-
tological toxicity at a dose of carboplatin AUC 3. At a carboplatin
dose of AUC 4, myelosuppression became more common and
significant. The first patient at AUC 4 tolerated two cycles of
treatment without significant toxicity. The second patient experi-
enced grade 4 neutropenia and thrombocytopenia with the first
cycle of treatment, but recovered to receive the second cycle after
the required interval. The third patient also experienced grade 4
neutropenia and thrombocytopenia. However, as the first two
patients had tolerated the treatment with minimal subjective
toxicity and recovered to receive further treatment on schedule,
the dose was then escalated to AUC 5 in accordance with
the protocol. Dose escalation should have stopped after two
patients experienced DLT, but this only became apparent after
the first patient at AUC 5 had tolerated that dose well, which in
retrospect led us to treat three further patients at AUC 5
incorrectly.
At AUC 5, the first patient completed two cycles of treatment
without significant haematological toxicity. The second patient
died on day 15 of treatment. This patient had multiple sites of
disease at diagnosis, including liver, splenic and lung metastases,
and was taking nonsteroidal analgesia for back pain from bone
metastases. On day 6 after the first cycle of treatment, analgesia
was increased because of worsening back pain, and on day 15 the
patient had a suspected intra-abdominal catastrophe after an
episode of vomiting. There was no obvious haematemesis or
melaena, so it is unknown whether this was a bleeding
complication. The patient did not have a full blood count (it was
due that day), so it is unknown whether she was myelosuppressed
at the time of death. A postmortem was refused. This was thus
recorded as an early death, although it is unknown to what extent
chemotherapy contributed to her death.
Table 1 Patient characteristics
Total number of patients 30
Sex
Male 16
Female 14
Age (years)
Median 54
Range 40–81
ECOG performance status
01 6
11 0
24
Time to distant progression from diagnosis (months)
Median 35.4
Range 0–126
Site of disease
Skin/soft tissue 14
Nodal disease 9
Lung 15
Liver 11
Brain 11
Bone 5
Visceral disease (nonhepatic) 4
Single site only 8
ECOG¼Eastern Cooperative Oncology Group.
Table 2 Dose escalations
Carboplatin dose
No. assessable
patients No. courses
No. with
DLT
Stage 1: Temozolomide dose 750mgm
 2
AUC 3 3 10 0
AUC 4 3 11 0
AUC 5 3 7 0
AUC 6 3 5 0
Stage 2: Temozolomide dose 1000mgm
 2
AUC 3 3 13 0
AUC 4 11 35 8
AUC 5 4 8 2
DLT¼dose limiting toxicity.
AUC=Area under curve.
Table 3 Stage 1 grade of haematological toxicity
01 2
Cycles (patients)
Carboplatin AUC 3
Anaemia 6 (3) 2(1) 2 (1)
Thrombocytopenia 10 (3) 0(0) 0 (0)
Neutropenia 9 (3) 1(1) 0 (0)
Carboplatin AUC 4
Anaemia 4 (3) 6 (3) 1 (1)
Thrombocytopenia 4 (3) 6 (3) 1 (2)
Neutropenia 6 (3) 5 (3) 0 (0)
Carboplatin AUC 5
Anaemia 5 (3) 2 (2) 0 (0)
Thrombocytopenia 5 (3) 2 (1) 0 (0)
Neutropenia 5 (3) 2 (1) 0 (0)
Carboplatin AUC 6
Anaemia 4 (2) 0 (0) 1 (1)
Thrombocytopenia 4 (3) 1 (1) 0 (0)
Neutropenia 4 (3) 1 (1) 0 (0)
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lTwo further patients were treated at this dose level, one of whom
experienced grade 3 haematological toxicity after the second cycle
of treatment, and the other grade 4 haematological toxicity. There
were no infectious complications; however, the fourth patient
treated at this level required blood transfusions after cycles 1, 2,
and 3, and a platelet transfusion after cycle 4 for an episode of
epistaxis. Imaging at this time demonstrated a partial response.
The patient, however, was considered not to be fit for further
chemotherapy due to general debilitation and the response was not
sustained. The DLT was thus haematological at carboplatin AUC 5
and further patients were treated at carboplatin AUC 4 to gain
further information about tolerability.
In the total cohort of 11 patients treated at carboplatin AUC 4,
haematological toxicity remained significant (Table 4). Thrombo-
cytopenia was a frequent toxicity, with six patients experiencing
grade 4 toxicity, in 16 of 32 cycles administered. The platelet nadir
in all cases was at day 21, but was generally transient and there was
only one episode of epistaxis for which the patient received platelet
support. The majority of patients recovered their platelet count in
time for the next treatment cycle; however, five cycles were delayed
because of thrombocytopenia. The dose of carboplatin was
reduced in two patients. One patient required a 2-week treatment
delay after the first cycle of treatment, and the dose of carboplatin
was reduced to AUC 3. Despite this, further thrombocytopenia
causing treatment delay was observed and the carboplatin dose
was reduced to AUC 2 for the fourth cycle. Grade 4 thrombocy-
topenia occurred once again and due to ongoing myelosuppression
treatment was stopped. The second patient experienced significant
anaemia and thrombocytopenia, and the carboplatin dose was
reduced to AUC 3 for the sixth cycle of treatment after a 2-week
treatment delay for neutropenia.
Neutropenia was observed less frequently. However, prolonged
neutropenia resulted in treatment delay in five cycles, and dose
reduction was required in two patients. Furthermore, two patients
experienced grade 4 toxicity, in one case resulting in neutropenic
sepsis requiring hospital admission. This patient died of probable
cardiac failure while in hospital following treatment for neutro-
penic sepsis, although bone marrow recovery had occurred at the
time of death. Prolonged neutropenia resulted in treatment delay
in five cycles, and dose reduction was required in two patients.
With expansion of the AUC 4 cohort, grade 3/4 myelosuppres-
sion remained significant and common, and was thus not found to
be the maximum tolerated dose.
Nonhaematological toxicities
Nonhaematological toxicity was mild, but included gastrointestinal
toxicity, with grade 1 nausea and vomiting in six patients, grade 2
in two patients and grade 3 in three patients. Six patients also
experienced grade 1 constipation and one grade 3. Five patients
experienced grade 1 mucositis. There was no renal or hepatic
toxicity.
Response
Stage 1 No patients in phase 1 responded to the treatment
combination, athough three patients achieved transient stabilisa-
tion of their disease. In all, 12 patients progressed on treatment.
Stage 2 Two of 18 patients were not assessable for response due
to early death or deterioration. In the whole cohort, two patients
achieved a partial response to treatment, one patient in cohort 1
(carboplatin AUC 3) and one patient in cohort 2 at carboplatin
AUC 4. Both patients had multiple sites of disease, including lung
and soft tissue, and one patient also had liver involvement. Three
patients achieved disease stabilisation, and the other 11 patients
progressed on treatment. The median duration of response in the
two patients achieving a partial response was 7.2 months.
The median overall survival in this group of patients was 5.6
months.
Two patients with stable disease after six cycles of the
combination received six further cycles of temozolomide alone.
The treatment was well tolerated in both patients, and no
progression of disease was seen while they remained on treatment.
One patient progressed 4 months after the completion of treatment
and the other 11 months later.
DISCUSSION
Chemotherapy for patients with advanced melanoma is largely
palliative with short survival times, thus outpatient regimens with
low toxicity are preferable. Temozolomide is an attractive agent for
use in melanoma, as it has excellent oral bioavailability, it
penetrates the CSF and has the same active component as DTIC,
the standard therapy for melanoma. In the Cancer Research
Campaign (CRC) phase II trial of temozolomide in melanoma, the
results were promising, with an overall response rate of 21% in 49
patients assessable for response. Most patients had multiple sites
of metastases. All patients initially received 750mgm
 2 given over
5 days, and if no grade 3 or 4 toxicity was observed, subsequent
courses were administered at 1000mgm
 2 again given over 5 days.
In 43 of 55 patients, dose escalation was possible and only two
episodes of grade 4 thrombocytopenia and five episodes of grade 4
neutropenia were observed. Tolerability was confirmed in a large
phase III trial comparing temozolomide with DTIC, where only 64
of 581 cycles (11%) resulted in grade 3 or 4 neutropenia or
thrombocytopenia. In all, 3% of patients discontinued treatment
due to adverse events.
Here, when carboplatin (AUC 3–6) was added to temozolomide
at 750mgm
 2, the regimen was well tolerated with no grade 3 or 4
toxicity. However, when the temozolomide dose was increased to
the recommended phase II dose of 1000mgm
 2 myelosuppression
became more common and significant. The DLT was haematolo-
gical at carboplatin AUC 5 with two of four patients experiencing
grade 3/4 thrombocytopenia and neutropenia. At this dose, there
was also an early death on day 15 of the first treatment cycle. Eight
patients, in addition to the initial cohort of three patients, were
treated at a carboplatin dose of AUC 4 to further assess toxicity.
This demonstrated persistent significant myelosuppression with 16
of 32 cycles (50%), resulting in grade 4 thrombocytopenia. In
addition, four patients experienced grade 3 or 4 neutropenia,
which resulted in neutropenic sepsis requiring hospitalisation
admission in one patient. Two patients discontinued treatment due
to toxicity, one due to ongoing myelosuppression despite two dose
reductions and the other due to general debility after four cycles.
Table 4 Stage 2 grade of haematological toxicity
01 2 3 4
Cycles (patients)
Carboplatin AUC 3
Anaemia 2 (1) 10 (3) 2 (2) 0 (0) 0 (0)
Thrombocytopenia 7 (3) 2 (1) 5 (2) 0 (0) 0 (0)
Neutropenia 11 (3) 3 (2) 0 (0) 0 (0) 0 (0)
Carboplatin AUC 4
Anaemia 20 (9) 6 (4) 3 (3) 2 (1) 1 (1)
Thrombocytopenia 13 (4) 0 (0) 0 (0) 3 (2) 16 (6)
Neutropenia 17 (5) 2 (2) 7 (2) 3 (2) 3 (2)
Carboplatin AUC 5
Anaemia 4 (3) 1 (1) 1 (1) 1 (1) 0 (0)
Thrombocytopenia 2 (1) 0 (0) 0 (0) 3 (2) 2 (1)
Neutropenia 3 (2) 1 (1) 0 (0) 2 (2) 1 (1)
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lOwing to the significance of the toxicity in the expanded cohort at
carboplatin AUC 4, this was not the MTD.
Although response was not a primary end point, the response
rate was poor in both phases of the trial. At 750mgm
 2
temozolomide no patients responded to treatment, although
three out 12 achieved disease stabilisation. At 1000mgm
 2
temozolomide, two of 18 patients achieved a partial response,
and a further three achieved disease stabilisation. Thus, the overall
response rate was two of 28 (7%). There were no responses noted
in any of the 11 patients with brain metastases. This appears
inferior to results from the initial phase I trial of temozolomide
that included 23 patients with metastatic melanoma (Newlands
et al, 1992). There, four patients (17%) responded to temozolo-
mide, two at 750mgm
 2 and two at 1000mgm
 2 using the same 5-
day scheduling. In general, higher response rates have been
observed in subcutaneous and lymph node disease, although in the
CRC phase II study of temozolomide as a single agent there were
three complete responses in patients with lung metastases, and
partial responses noted in another nine patients with miscella-
neous sites of disease. There were no responses in the brain
metastases of four patients. The disease mix here was similar to
that in the CRC phase II trial, with 71% patients in our trial having
multiple sites of disease, compared to 80% in the CRC trial.
However, there was a much higher patient number with brain
metastases in the present study (37%). It is disappointing that no
responses occurred in our study in patients with cerebral
metastases as temozolomide is known to cross the blood–brain
barrier, and responses are found in primary brain tumours. In the
larger phase III trial where 156 patients received temozolomide,
the overall response rate was 13.5%. It was not stated how many
patients had multiple sites of metastases, but patients with cerebral
metastases were excluded from the trial. A recent phase II trial
examined a combination of docetaxel and temozolomide
1000mgm
 2 given 4-weekly in 62 patients with metastatic
melanoma (Bafaloukos et al, 2002). Again the treatment was well
tolerated with only eight patients (13%) experiencing grade 3/4
thrombocytopenia, and an overall response rate of 27% was
achieved. Three of eight patients with brain metastases responded
to treatment.
Despite the poor response rate of the combination of treatment
in the present study, the median survival in this group of patients
was 5.6 months, which was in keeping with that of treatment with
other chemotherapy agents.
In conclusion, the addition of carboplatin to temozolomide
1000mgm
 2 significantly adds to myelosuppression when the
carboplatin dose is escalated over AUC 3. Grade 4 thrombocyto-
penia is common at day 21 with carboplatin AUC 4, although the
regimen is otherwise well tolerated. In this population of patients,
with a high proportion of brain metastases, the response rates were
low (7%) and less than previously reported. Owing to poor
response rates, it was not thought justifiable to expand the cohort
of patients receiving a carboplatin dose of AUC 3, and thus the
MTD was not defined. It is unlikely that the combination of
temozolomide and carboplatin can be given in sufficient doses to
improve on the efficacy of temozolomide given as a single agent in
advanced melanoma.
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